Silo Pharma, Inc., a biopharmaceutical company in the developmental stage, is collaborating with Resyca to conduct a drug-device study of its PTSD treatment, SPC-15. This intranasal medication aims to alleviate symptoms of post-traumatic stress disorder and stress-induced anxiety.
Silo Pharma focuses on creating innovative therapies for conditions that lack sufficient treatment options, such as stress-related psychiatric disorders and chronic pain. The company actively seeks to acquire or develop intellectual property and technology from academic institutions and researchers to address rare diseases. One area of exploration includes the use of psychedelic substances, like psilocybin, which have shown promise in treating various mental health issues, including depression and neurological disorders.
SPC-15 is designed to be administered intranasally, providing a new approach to treating PTSD. Additionally, Silo Pharma has developed another product, SP-26, which is a time-release ketamine-loaded implant aimed at relieving fibromyalgia and chronic pain. The company also has two preclinical programs underway: SPC-14, which targets Alzheimer’s disease, and SPU-16, a peptide designed to treat multiple sclerosis.
The partnership with Resyca marks a strategic move to enhance the development of SPC-15, highlighting the growing interest in innovative treatments for mental health conditions. As the study progresses, findings will contribute to a better understanding of how this drug-device combination can be used effectively in clinical settings, potentially offering new hope for individuals suffering from PTSD.
Belarusian 
English 
French 
German 
Russian 
Spanish 
Ukrainian